EUVIMEDAtklāt EUVIMED
Crossref

Exploring Material Basis and Q‐Markers for Treatment of Alcoholic Liver Disease With Tetracera asiatica Tablets Based on In Vitro Components—In Vivo Transferring Components—Efficacy Targets

Da Fangfang, Yuan Ziwan iD, Liu Ying, Chen Yufeng, Meng Yaoting, Wang Xiangpei iD

Biomedical Chromatography · 2026-12 · 40 (12)

DOI: 10.1002/bmc.70653 ↗

At a glance

Journal article in Biomedical Chromatography, published online on 2026-11-11. Written by Da Fangfang and 5 co-authors. Institution: School of Chinese Ethnic Medicine, GuiZhou Minzu University, Guiyang, China. Major MEDLINE topics: Liver Diseases, Alcoholic, Drugs, Chinese Herbal. 52 references.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

This study aimed to clarify the therapeutic material basis of Tetracera asiatica (TA) against alcoholic liver disease (ALD) and predict its potential quality markers (Q‐markers). UPLC‐Q‐Exactive Orbitrap HRMS, Progenesis QI 3.0 and reference compound database were adopted to characterize in vitro constituents, in vivo prototypes and postintragastric metabolites. Targets retrieved from multiple databases were used to construct a component–target–disease network, and molecular docking was performed to evaluate binding affinity. The ethanol extract of TA alleviated ethanol‐induced increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Among 170 characterized constituents, 49 were detected in mouse serum and liver, and 350 overlapping targets between TA and ALD were screened. Kaempferol, eriodictyol, ellagic acid, catechin, quercetin, and naringenin were key active constituents, functioning through HIF‐1, AGE‐RAGE, and JAK–STAT pathways and showing strong binding to SRC proto‐oncogene, non‐receptor tyrosine kinase (SRC), B‐cell lymphoma‐2 (BCL2), and epidermal growth factor receptor (EGFR). These six compounds constitute the core pharmacodynamic material basis of TA against ALD and are promising candidate Q‐markers based on specificity, detectability, efficacy correlation, bioavailability, and TCM theory.

Subjects

MeSH terms (MEDLINE)

Liver Diseases, AlcoholicDrugs, Chinese HerbalAnimalsMiceMaleTabletsBiomarkersMolecular Docking SimulationChromatography, High Pressure LiquidPlant ExtractsLiver

Author keywords

Tetracera asiaticaUPLC‐Q‐Exactive Orbitrap HRMSmaterial basis of pharmacodynamicsnetwork pharmacologyquality markers

Substances

TabletsBiomarkersDrugs, Chinese HerbalPlant Extracts

Authors and institutions

  • School of Chinese Ethnic Medicine, GuiZhou Minzu University, Guiyang, China.
  • Key Laboratory of Guizhou Ethnic Medicine Resource Development and Utilization, Guizhou Minzu University, Guiyang, China.

ORCID profiles: Yuan Ziwan, Wang Xiangpei

Cite

APA

Fangfang, D., Ziwan, Y., Ying, L., Yufeng, C., Yaoting, M., & Xiangpei, W. (2026). Exploring Material Basis and Q‐Markers for Treatment of Alcoholic Liver Disease With Tetracera asiatica Tablets Based on In Vitro Components—In Vivo Transferring Components—Efficacy Targets. Biomedical Chromatography, 40(12). https://doi.org/10.1002/bmc.70653

Vancouver

Fangfang D, Ziwan Y, Ying L, Yufeng C, Yaoting M, Xiangpei W. Exploring Material Basis and Q‐Markers for Treatment of Alcoholic Liver Disease With Tetracera asiatica Tablets Based on In Vitro Components—In Vivo Transferring Components—Efficacy Targets. Biomedical Chromatography. 2026;40(12). doi:10.1002/bmc.70653

BibTeX
@article{Fangfang2026,
  author = {Fangfang, Da and Ziwan, Yuan and Ying, Liu and Yufeng, Chen and Yaoting, Meng and Xiangpei, Wang},
  title = {Exploring Material Basis and Q‐Markers for Treatment of Alcoholic Liver Disease With Tetracera asiatica Tablets Based on In Vitro Components—In Vivo Transferring Components—Efficacy Targets},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {12},
  doi = {10.1002/bmc.70653}
}
Start for free →